TARS compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

TARSTarsus Pharmaceuticals, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

TARSTarsus Pharmaceuticals, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TARS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26thin chain±12.8%▼−4.91%×0.38

Q2 FY26±10.5%▲+6.59%×0.63

Q1 FY26±13.4%▼−1.24%×0.09

Feb 24 '26±14.8%▲+7.79%×0.53

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedTARS realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 15%× = |realized| ÷ impliedSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

TARSTarsus Pharmaceuticals, Inc.

67.46· pre 66.23· delayed

Mkt cap$3.4BRevenue$195MQ3 FY26Revenue$451MFY25

AMGNAmgen Inc

461.49· pre 448.53· delayed

Pre-marketNov 6 '26delayed

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Pre-marketNov 6 '26delayed

TARSTarsus Pharmaceuticals, Inc.

AMGNAmgen Inc

67.46pre 66.23delayed

Price

461.49pre 448.53delayed

$3.4B

Mkt cap

$249.0B

Q3 FY26$195M

Revenue

$10.4BQ3 FY26

FY25$451M

Revenue

$36.8BFY25

TARS67.46vsAMGN461.49Pre-marketNov 6 '26delayed